High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies

Molecular and Cellular Proteomics

Volumn 13, Issue 12, 2014, Pages 3320-3331

  Ha, Kevin D ^a   Bidlingmaier, Scott M ^a   Zhang, Yafeng ^a   Su, Yang ^a   Liu, Bin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; TUMOR ANTIGEN; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CANCER ANTIBODY; EPHRIN RECEPTOR A2; IMMUNOGLOBULIN G; IMMUNOTOXIN; PEPTIDE LIBRARY; RIBOSOME INACTIVATING PROTEIN 1; SAPORIN;

ANTIBODY LIBRARY; ARTICLE; CONTENT ANALYSIS; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; LASER CAPTURE MICRODISSECTION; MALE; PINOCYTOSIS; PRIORITY JOURNAL; TARGET CELL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; FIBROBLAST; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HIGH THROUGHPUT SCREENING; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PEPTIDE LIBRARY;

ANTIBODIES, NEOPLASM; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BIOMARKERS; CELL LINE; CELL LINE, TUMOR; FIBROBLASTS; GENE EXPRESSION; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNOGLOBULIN G; IMMUNOTOXINS; LASER CAPTURE MICRODISSECTION; MOLECULAR TARGETED THERAPY; PEPTIDE LIBRARY; PINOCYTOSIS; RECEPTOR, EPHA2; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84928237102     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M114.039768     Document Type: Article

References (38)

1. Ruan, W., Sassoon, A., An, F., Simko, J. P., and Liu, B. (2006) Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol. Cell. Proteomics. 5, 2364-2373
2. Austin, C. D., De Maziere, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., and Scheller, R. H. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15, 5268-5282
3. Burris, H. A., 3rd, Tibbitts, J., Holden, S. N., Sliwkowski, M. X., and Lewis Phillips, G. D. (2011) Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin. Breast Cancer 11, 275-282
4. Sievers, E. L., and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29
5. Behrens, C. R., and Liu, B. (2013) Methods for site-specific drug conjugation to antibodies. MAbs. 6, 46-53
6. Sutherland, M. S., Sanderson, R. J., Gordon, K. A., Andreyka, J., Cerveny, C. G., Yu, C., Lewis, T. S., Meyer, D. L., Zabinski, R. F., Doronina, S. O., Senter, P. D., Law, C. L., and Wahl, A. F. (2006) Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281, 10540-10547
7. Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., and Blattler, W. A. (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66, 4426-4433
8. Hewlett, L. J., Prescott, A. R., and Watts, C. (1994) The coated pit and macropinocytic pathways serve distinct endosome populations. J. Cell Biol. 124, 689-703
9. Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., Rabinowitz, J. D., Metallo, C. M., Vander Heiden, M. G., and Bar-Sagi, D. (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633-637
10. Hayward, S. W., Dahiya, R., Cunha, G. R., Bartek, J., Deshpande, N., and Narayan, P. (1995) Establishment and characterization of an immortalized but nontransformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev. Biol. Anim. 31, 14-24
11. O'Connell, D., Becerril, B., Roy-Burman, A., Daws, M., and Marks, J. D. (2002) Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Mol. Biol. 321, 49-56
12. Liu, B., and Marks, J. D. (2000) Applying phage antibodies to proteomics: selecting single chain Fv antibodies to antigens blotted on nitrocellulose. Anal. Biochem. 286, 119-128
13. Zhu, X., Bidlingmaier, S., Hashizume, R., James, C. D., Berger, M. S., and Liu, B. (2010) Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol. Cancer Ther. 9, 2131-2141
14. An, F., Drummond, D. C., Wilson, S., Kirpotin, D. B., Nishimura, S. L., Broaddus, V. C., and Liu, B. (2008) Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol. Cancer Ther. 7, 569-578
15. Liu, B., Conrad, F., Cooperberg, M. R., Kirpotin, D. B., and Marks, J. D. (2004) Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 64, 704-710
16. Smith, K., Garman, L., Wrammert, J., Zheng, N. Y., Capra, J. D., Ahmed, R., and Wilson, P. C. (2009) Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372-384
17. Liu, B., Conrad, F., Roth, A., Drummond, D. C., Simko, J. P., and Marks, J. D. (2007) Recombinant full-length human IgG1s targeting hormonerefractory prostate cancer. J. Mol. Med. 85, 1113-1123
18. Conrad, F., Zhu, X., Zhang, X., Chalkley, R. J., Burlingame, A. L., Marks, J. D., and Liu, B. (2009) Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J. Mol. Med. 87, 507-514
19. Keller, A., Nesvizhskii, A. I., Kolker, E., and Aebersold, R. (2002) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383-5392
20. Nesvizhskii, A. I., Keller, A., Kolker, E., and Aebersold, R. (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646-4658
21. Schnatwinkel, C., Christoforidis, S., Lindsay, M. R., Uttenweiler-Joseph, S., Wilm, M., Parton, R. G., and Zerial, M. (2004) The Rab5 effector Ra-bankyrin-5 regulates and coordinates different endocytic mechanisms. PLoS Biol. 2, E261
22. Veithen, A., Amyere, M., Van Der Smissen, P., Cupers, P., and Courtoy, P. J. (1998) Regulation of macropinocytosis in v-Src-transformed fibroblasts: cyclic AMP selectively promotes regurgitation of macropinosomes. J. Cell Sci. 111, 2329-2335
23. Gold, S., Monaghan, P., Mertens, P., and Jackson, T. (2010) A clathrin independent macropinocytosis-like entry mechanism used by bluetongue virus-1 during infection of BHK cells. PLoS One. 5, e11360
24. Veithen, A., Cupers, P., Baudhuin, P., and Courtoy, P. J. (1996) v-Src induces constitutive macropinocytosis in rat fibroblasts. J. Cell Sci. 109, 2005-2012
25. West, M. A., Bretscher, M. S., and Watts, C. (1989) Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J. Cell Biol. 109, 2731-2739
26. Wykosky, J., and Debinski, W. (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res. 6, 1795-1806
27. Tandon, M., Vemula, S. V., and Mittal, S. K. (2011) Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert. Opin. Ther. Targets. 15, 31-51
28. Reyes-Reyes, E. M., Teng, Y., and Bates, P. J. (2010) A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 70, 8617-8629
29. Poul, M. A., Becerril, B., Nielsen, U. B., Morisson, P., and Marks, J. D. (2000) Selection of tumor-specific internalizing human antibodies from phage libraries. J. Mol. Biol. 301, 1149-1161
30. Rudnick, S. I., Lou, J., Shaller, C. C., Tang, Y., Klein-Szanto, A. J., Weiner, L. M., Marks, J. D., and Adams, G. P. (2011) Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 71, 2250-2259
31. Chakraborty, S., Veettil, M. V., Bottero, V., and Chandran, B. (2012) Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc. Natl. Acad. Sci. U. S. A. 109, E1163-E1172
32. Ansuini, H., Meola, A., Gunes, Z., Paradisi, V., Pezzanera, M., Acali, S., Santini, C., Luzzago, A., Mori, F., Lazzaro, D., Ciliberto, G., Nicosia, A., La Monica, N., and Vitelli, A. (2009) Anti-EphA2 antibodies with distinct in vitro properties have equal in vivo efficacy in pancreatic cancer. J. Oncol. 2009, 951917
33. Jackson, D., Gooya, J., Mao, S., Kinneer, K., Xu, L., Camara, M., Fazenbaker, C., Fleming, R., Swamynathan, S., Meyer, D., Senter, P. D., Gao, C., Wu, H., Kinch, M., Coats, S., Kiener, P. A., and Tice, D. A. (2008) A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 68, 9367-9374
34. Zhou, Y., Zou, H., Zhang, S., and Marks, J. D. (2010) Internalizing cancer antibodies from phage libraries selected on tumor cells and yeast-displayed tumor antigens. J. Mol. Biol. 404, 88-99
35. Peng, L., Oganesyan, V., Damschroder, M. M., Wu, H., and Dall'Acqua, W. F. (2011) Structural and functional characterization of an agonistic anti-human EphA2 monoclonal antibody. J. Mol. Biol. 413, 390-405
36. Shen, H., Rodriguez-Aguayo, C., Xu, R., Gonzalez-Villasana, V., Mai, J., Huang, Y., Zhang, G., Guo, X., Bai, L., Qin, G., Deng, X., Li, Q., Erm, D. R., Aslan, B., Liu, X., Sakamoto, J., Chavez-Reyes, A., Han, H. D., Sood, A. K., Ferrari, M., and Lopez-Berestein, G. (2013) Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin. Cancer Res. 19, 1806-1815
37. Tanaka, T., Mangala, L. S., Vivas-Mejia, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H. D., Shahzad, M. M., Liu, X., Bhavane, R., Gu, J., Fakhoury, J. R., Chiappini, C., Lu, C., Matsuo, K., Godin, B., Stone, R. L., Nick, A. M., Lopez-Berestein, G., Sood, A. K., and Ferrari, M. (2010) Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 70, 3687-3696
38. Annunziata, C. M., Kohn, E. C., LoRusso, P., Houston, N. D., Coleman, R. L., Buzoianu, M., Robbie, G., and Lechleider, R. (2013) Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest. New Drugs. 31, 77-84